IMPFSTOFF FÜR GEFLÜGEL

PROCEDURE FOR THE PRODUCTION OF THE VIRUS OF THE INFECTIOUS ONES BURSITIS FROM SYNTHETIC RNS TRANSKRIPTEN

VACCINE FOR POULTRY

FOWL CHOLERA VACCINE

HAEMOPHILUS PARAGALLINARUM VACCINE

MYCOPLASMA VACCINE

The present invention is concerned with a nove Mycoplasma vaccine which is avirulent for chickens an is not pathogenic for turkeys. In particular such vaccine contains the Mycoplasma strain Intervet 6/8 (deposit No. I-673 at CNCM, Pasteur Institute, Paris France).

IMMUNIZING COMPOSITIONS AND METHODS OF USE

The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccharide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods making and methods of using such compositions.

LIVE IN OVO VACCINE

TITLE: Live In Ovo Vaccine The present invention relates generally to modified microorganisms suitable for use as live in ovo vaccines for avian species. The live in ovo vaccines of the present invention are useful for inducing immunity before or immediately after hatching against a virulent form of the modified microorganism or a microorganism immunologically related to the modified microorganism or a virulent organism or virus carrying an antigenlc determinant expressed by the modified microorganism in the live vaccine. The subject live in ovo vaccines are particularly efficacious in engancing the survival rate of newlyhatched poultry birds.

ACTIVE IMMUNIZATION USING A SIDEROPHORE RECEPTOR PROTEIN

The invention provides a vaccine for immunizing poultry and other animals against infection by a gram-negative bacteria, and a method of immunizing an animal using the vaccine. The vaccine may contain purified siderophore receptor proteins derived from a single strain or species of gram-negative bacteria or other organisms, which are cross-reactive with siderophores produced by two or more strains, species or genera of gram-negative bacteria. The invention further provides a process for isolating and purifying the siderophore receptor proteins, and for preparing a vaccine containing the proteins. Also provided is a method for diagnosing gram-negative sepsis.

NON-VIRULENT MYCOPLASMA SYNOVIAE AND VACCINE THEREOF

The present invention provides NAD-independent Mycoplasma synoviae of strain MS1. The invention also refers to microbiological cultures comprising Mycoplasma synoviae of this strain. Next to this, the invention refers to live vaccines derived fro m these strains, for the protection of poultry against Mycoplasma synoviae infection. Furthermore , the invention provides methods for the preparation of such vaccines. Also, the u se of NAD-independent Mycoplasma synoviae strains for the preparation of live vaccines for the protection of poultry against Mycoplasma synoviae infection is disclosed. ...

A METHOD FOR GENERATING BIRNAVIRUS FROM SYNTHETIC RNA TRANSCRIPTS

A system for the generation of live Birnavirus such as infectious bursal disease virus (IBDV), a segmented double-stranded (ds)RNA virus of the Birnavirdae family, using synthetic transcripts derived from cloned DNA has been developed. Independent full-length cDNA clones were constructed which contained the entire coding and non-coding regions of RNA segments A and B of IBDV, respectively. Synthetic RNAs of both segments were produced by in vitro transcription of linearized plasmids with T7 RNA polymerase. Transfection of Vero cells with combined plus-sense transcripts of both segments generate d infectious virus as early as 36 hours post-transfection. The development of a reverse genetics system for dsRNA viruses will greatly facilitate studies of the regulation of viral gene expression pathogenesis, and design of a new generation of live and inactivated vaccine s.

USE OF OPRI LIPOPROTEIN FROM PSEUDOMONAS AS A TH1 INDUCING NATURAL ADJUVANT FOR HETEROLOGOUS ANTIGENS

The present invention relates to the use of the major OprI lipoprotein of Pseudomonas aeruginosa to elicit a Type-1 immune response towards a heterologous antigen. The invention relates specifically to the use of Oprl - antigen fusion proteins to elicit said Typ-1 response. More particurarly, the present invention is directed to pharmaceutical formulations comprising Oprl and/or Oprl fusion proteins, optionnaly together with a suitable excipient, to stimulate the Th1 dependent, cellular immune response.

Cross-protective fowl cholera bacterins

Cross-protection of fowl against different serologic and immunologic types of Pasteurella multocida, responsible for fowl cholera, has been achieved by a novel process for preparing P. multocida bacterins. Bacterial cells from infected fowl tissue are passaged only once through a laboratory medium, sterilized, and recovered for use.

Methods for treating high somatic cell counts

The present invention provides methods for treating an animal having a high somatic cell count. The methods include administering compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter.

Fowl cholera vaccine

LIVING VACCINES.

POULTRY ILLNESS CAUSING NEW BACTERIUM AND FROM THIS COMING VACCINE

NOT VIRULENTES MYCOPLASMA SYNOVIAE AND VACCINES OF THE SAME

ATTENUIERTES LEBENDVAKZIN FOR USE IN EGGS

IMMUNIZING COMPOSITIONS AND METHODS OF USE

The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.

Beta-1,4-mannobiose-containing composition

VACCINE AGAINST THE CHOLERA OF THE POULTRY

VACCIN CONTRE LE CHOLERA DE LA VOLAILLE

L'INVENTION CONCERNE UN VACCIN VIVANT CONTRE LE CHOLERA DE LA VOLAILLE POUVANT ETRE ADMINISTRE PAR INJECTION, PAR VOIE BUCCALE OU SOUS FORME D'AEROSOL. LE VACCIN DE L'INVENTION CONTIENT UNE SOUCHE ATTENUEE NON VIRULENTE, GENETIQUEMENT STABLE DE PASTEURELLA MULTOCIDA.

VACCIN VIVANT POUR LA PREVENTION DE LA SALMONELLOSE DES OISEAUX AQUATIQUES ET PROCEDE POUR SA PREPARATION

LA PRESENTE INVENTION CONCERNE UN NOUVEAU VACCIN VIVANT POUR LA PREVENTION DE LA SALMONELLOSE DES OISEAUX QUI EST UNE SUSPENSION D'UNE CULTURE VIVANTE DE LA SOUCHE ATTENUEE DE SALMONELLA TYPHI-MURIUM N3, DEPOSEE A L'INSTITUT PANSOVIETIQUE SCIENTIFIQUE DE CONTROLE DES PREPARATIONS VETERINAIRES DU MINISTERE DE L'AGRICULTURE DE L'URSS, A UNE CONCENTRATION DE 2 A 4MILLIARDS DE CELLULES MICROBIENNES PAR 10CM D'EAU POTABLE. LE PROCEDE DE PREPARATION DU NOUVEAU VACCIN VIVANT CONSISTE A CULTIVER LA SOUCHE ATTENUEE DE SALMONELLA TYPHI-MURIUM N3 SUR UN MILIEU NUTRITIF, CONTENANT DES SOURCES DE CARBONE ET D'AZOTE, DES SELS MINERAUX ET DES SUBSTANCES BIOLOGIQUEMENT ACTIVES, A UNE TEMPERATURE DE 37 A 38C JUSQU'A UNE ACCUMULATION MAXIMALE, PENDANT 10 A 14HEURES, AVEC SECHAGE SUBSEQUENT ET OBTENTION DU VACCIN.

VACCINES AND THEIR PREPARATION

Bacterial preparations, method for producing same, and their use as vaccines

Novel bacterial preparations containing one or more isolated and purified strain of a microorganism which produces one or more RTX toxins, and which strain has at least one RTX toxin which is substantially cell-associated. Methods of preparing the bacterial preparations and their use as vaccines and to produce antibodies for passive immunization are described.

A method for generating birnavirus from synthetic RNA transcripts

A system for the generation of live Birnavirus such as infectious bursal disease virus (IBDV), a segmented double-stranded (ds)RNA virus of the Birnavirdae family, using synthetic transcripts derived from cloned DNA has been developed. Independent full-length cDMA clones were constructed which contained the entire coding and noncoding regions of RNA segments A and B of IBDV, respectively. Synthetic RNAs of both segments were produced by in viro transcription of linearized plasmids with T7 RNA polymerase. Transfection of Vero cells with combined plus-sense transcripts of both segments generated infectious virus as early as 36 hours post-transfection. The development of a reverse genetics system for dsRNA viruses will greatly facilitate studies of the regulation of viral gene expression pathogenesis, and design of a new generation of live and inactivated vaccines.

LIVE VACCINES

AKTIVE IMMUNISIERUNG GEGEN EIN SIDEROPHORES REZEPTORPROTEIN

IMPFSTOFF FÜR GEFLÜGEL

Nicht-virulentes Mycoplasma synoviae und Impfstoffe desselben

LIVE VACCINES

VERFAHRN TO INOCULATING POULTRY APPROXIMATELY PASTEURELLA MULTOCIDA

USE OF OPRI LIPOPROTEIN OUT PSEUDOMONAS AS TH1 INDUCING NATURAL ADJUVANS FOR HETEROLOGE ANTIGENS

LIVING VAKZINE

VERFAHRN ZUM IMPFEN VON GEFLUEGEL GEGEN PASTEURELLA MULTOCIDA

GEFLUEGELCOLIBACILLOSE VAKZIN.

Live in ovo vaccine

FOWL CHOLERA VACCINE

STABILIZED MYCOPLASMA VACCINE

POX VIRUS VECTORS

Recombinant fowlpox virus vectors in the form of vaccinia viruses have the potential to deliver vaccine antigens to a variety of animal species. Accordingly, a gene sequence is provided which includes a first promotor for the expression of a major early fowlpox virus protein as well as a second promotor for the expression of a late fowlpox virus protein in opposite orientation to the first promotor. A plasma may be provided which includes the gene sequence of the first and second promotors as well as a viral vector including the same sequences. A process for constructing the viral vector is also disclosed.

METHOD OF VACCINATION OF NEWLY HATCHED POULTRY

A method of vaccinating poultry by spraying the poultry with an effective amount of a live avirulent derivative of an enteropathogenic enterobacteria is disclosed.

METHOD FOR PREVENTING RESPIRATORY MYCOPLASMOSIS OF LIVESTOCK

Immunogenic hybrid protein OprF-OprI derived from Pseudomonas aeruginosa membrane proteins

The present invention relates to a hybrid protein comprising the Pseudomonas aeruginosa outer membrane protein I (OprI) which is fused with its amino terminal end to the carboxy-terminal end of a carboxy-terminal portion of the Pseudomonas aeruginosa outer membrane protein F (OprF), as well as to monoclonal or polyclonal antibodies against this hybrid protein. Both, the hybrid protein and the antibodies directed to the hybrid protein confer protection against an infection by Pseudomonas aeruginosa to laboratory animals or man.

Способ получения вакцины против респираторных заболеваний животных и птиц, вызываемых микоплазмами

Immunogenes Hybridprotein OprF-Oprl erhältlich aus Membranproteinen von Pseudomonas aeruginosa

Gefl}gelkrankheit verursachende neue Bakterie und daraus stammender Impfstoff.

ACTIVE ONE IMMUNISIERUNG AGAINST A SIDEROPHORES RECEPTOR PROTEIN

POXVIRUS VECTORS.

VERFAHRN TO INOCULATING POULTRY APPROXIMATELY PASTEURELLA MULTOCIDA

COMPOSITIONS TO IMMUNISIERUNG AS WELL AS THEIR USE

IMMUNOGEN HYBRID PROTEIN OPRF OPRL AVAILABLE FROM DIAPHRAGM PROTEINS OF PSEUDOMONAS AERUGINOSA

Campylobacter vaccine

METHOD FOR PREVENTING RESPIRATORY MYCOPLASMOSIS

POX VIRUS VECTORS

Active immunization using a siderophore receptor protein

METHOD OF VACCINATION OF NEWLY HATCHED POULTRY

... ▓▓▓A method of vaccinating poultry by spraying the poultry with an effective ▓amount of a live avirulent derivative of an enteropathogenic enterobacteria is ▓disclosed.▓ ...

PASTEURELLA MULTOCIDA VACCINE

Mutogenesis of the Clemson University (CU) vaccine strain of P. multocida with N-methyl-N-nitro-N-nitrosoguanidine resulted in temperature sensitive (TS) mutants which grew at 37°C but not 42°C. Two mutants, PM#1 and PM#3, were found to provide turkeys with a level of protection against challenge with a virulent serotype 3 P. multocida strain (P-1059) comparable to the protection provided by the CU strain. Intravenous (IV) inoculation of PM#1, PM#3, and CU was used to determine differences in virulence. PM#1 and PM#3 resulted in lower mortality and lameness than the CU strain. Histopathological evaluation of spleens at 24, 48, and 72 hours post IV inoculation demonstrated that the CU strain induced 2 times more splenic necrosis than either PM#1 or PM#3.

FLAGELLIN GENE, FLAC OF CAMPYLOBACTER

Purified and isolated nucleic acid molecules are provided which encode a FlaC flagellin protein of a strain of Campylobacter, particularly C. jejuni, or a fragment or an analog of the FlaC flagellin protein. The nucleic acid molecules may be used to produce proteins free of contaminants derived from bacteria normally containing the FlaA or FlaB proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecules, proteins encoded thereby and antibodies raised against the proteins, may be used in the diagnosis of infection.

CAMPYLOBACTER VACCINE

The present invention relates to vaccines comprising antiserum raised against a flagellaless Campylobacter strain for the prevention of Campylobacter colonisation in animals. The invention also relates to antigenic Campylobacter proteins visible in a Western blot of Campylobacter jejuni protein after incubation of said Western blot with antibodies against a flagellaless mutant of Campylobacter jejuni and not visible after incubation of said blot with antibodies against wild type Campylobacter jejuni, and to their use in vaccines and the manufacturing thereof. The invention further relates to vaccines comprising such proteins and antibodies against such proteins. The invention further relates to the use of such Campylobacter proteins and to antiserum and antibodies raised against Campylobacter antigens for the preparation of vaccines. Finally, the invention relates to methods for the preparation of such vaccines.

Method of vaccination of newly hatched poultry

METHOD OF VACCINATION OF NEWLY HATCHED POULTRY

Procédé servant à vacciner la volaille et consistant à pulvériser cette dernière au moyen d'une quantité efficace d'un dérivé vivant avirulent d'une entérobactérie entéropathogène.

METHOD FOR PREVENTING AND TREATING COCCIDIOSIS

A method for preventing and treating parasitic infections in animals by administering a lysine analog, such as EACA, to the animals on a continuous basis. In the preferred embodiment, the method of the present invention is directed to preventing and treating coccidial infections in poultry by adding EACA to the daily diet of a poultry flock. EACA may also be administered in ovo before hatching. The administration of EACA enhances the natural immune response of the poultry to the invading coccidial organisms and enables the poultry to combat the parasites without the need for antibiotics. Another aspect of the present invention involves preventing parasitic diseases in humans and animals by prophylactically administering a serine protease inhibitor, such as EACA, as an adjuvant in conjunction with a conventional vaccine effective against the target parasite.

Poultry vaccine against E. coli air sac inflammation and septicaemia

The present invention is concerned with vaccines effective in protecting poultry against E. coli septicaemia, which contain or can cause the production of fimbriae of the F11 type or an immunogenic section thereof, or antibodies against these.

Live vaccines

ZUSAMMENSETZUNGEN ZUR IMMUNISIERUNG SOWIE DEREN VERWENDUNG

LEBENDE VAKZINE

LIVE VACCINES

VACCINS ET LEUR PREPARATION

IMMUNIZING COMPOSITIONS AND METHODS OF USE

The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.

Pox virus vaccine

A gene sequence including a first promoter for the expression of a major early fowlpox virus (FPV) protein. In a preferred aspect, the gene sequence further includes a second promoter for the expression of a late fowlpox virus protein in opposite orientation to said first promoter. The promoter is useful in developing FPV based vectors for the delivery of vaccine antigens preferably to poultry, and as a tool to study the temporal regulation of poxvirus genes. The invention also offers methods useful in the construction of recombinant fowlpox viruses or related avian poxviruses, which methods are characterized by the introduction of foreign DNA into the fowlpox virus or into virus DNA sequences, which sequences are able to use native FPV promoter regions.

LIVE VACCINES

Attenuated microorganism for use in immunoprophylaxis in which the attenuation is brought about by the presence of a mutation in the DNA sequence of the microorganism which encodes, or which regulates the expression of DNA encoding a protein that is produced in response to environmental stress, the microorganism optionally being capable of expressing DNA encoding a heterologous antigen.

HAEMOPHILUS PARAGALLINARUM VACCINE

PURPOSE: To obtain Haemophilus paragallinarum vaccine having high prevention against Haemophilus paragallinarum infectious disease of edible pet birds and constitutionally including no cell having fear of causing a side effect and no fibrous material. CONSTITUTION: This Haemophilus paragallinarum(Hp) vaccine substantially includes no cell and no fibrous material, is derived from a membrane fraction of Hp cells containing about 38kD protein measured by SDS-PAGE, or an immunological equivalent thereof, preferably from external-membrane preparation containing the 38kD protein as a main protein component, especially from the membrane fraction of Hp cells having two or more different serotypes (e.g. serotypes A, B and C) and is a preventive vaccine for edible pet birds against Hp infectious disease. The bird vaccinated with an effective amount of the vaccine is completely prevented from catching the Hp infectious disease. The vaccine can includes one or more microorganism having infectivity ...

HAEMOPHILUS PARAGALLINARUM VACCINE

Beta-1,4-mannobiose-containing composition

TH1 inducing natural adjuvant for heterologous antigens

IMMUNOSTIMULATION METHODS FOR PROVIDING DISEASE PROTECTION IN POULTRY

Methods for providing improved immunization against coccidiosis and other bacterial, viral, or parasitic diseases in poultry. One method includes administering a solution of i(Propionibacterium acnes) suspended in normal saline to a chick at age day one, following hatching. An anticoccidial vaccine and/or other vaccine is then administered to the chick such as by oral administration. Alternatively, the method includes the steps of aseptically injecting i(Propionibacterium acnes in ovo) at about day 18 in development, followed by post-hatching vaccination with an anticoccidial vaccine and/or other vaccine. Alternatively, either method can be utilized without the subsequent vaccination step for stimulating non-specific cell-mediated immune responses in poultry.

Polypeptides obtained from gram negative microbes

The present invention provides compositions including at least two siderophore receptor polypeptides and at least two porins from a gram negative microbe, and preferably, lipopolysaccharide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of makino and methods of using such compositions.

NEW BACTERIUM CAUSING POULTRY DISEASE AND VACCINE DERIVED THEREOF

The present invention relates to a novel bacterial respiratory poultry disease and the identification of the causative agent. A vaccine derived from this agent was effective in preventing the disease in chickens challenged with the virulent field strains.

HAEMOPHILUS PARAGALLINARUM VACCINE

Abstract The invention is concerned with a vaccine for the protection of poultry against Haemophilus paragallinarum infection. Chickens vaccinated with a membraneous fraction of H. paragallinarum cells comprising a 38 kD outer-membrane protein are well protected against infection.

LIVE VACCINE HAVING AN INCREASED STABILITY

Abstract 1. Live vaccine having an increased stability 2.1 The safety of bacterial live vaccines is guaranteed by deletions, the stability of which with respect to in vivo repair lying in the range of about 10-12. The high requirements of the World Health Organisation and the wide-spread opinion about the alleged instability in the use of live vaccines under practical conditions let it appear to be necessary to enhance the already existing safety buffer by yet another increase of at least the factor 10-7. 2.2 The stability of a live vaccine produced from at least one metabolic drift attenuated, immunogenic, stable single or multiple marker live vaccine with or without envelope mutation and an optimal attenuation level adapted to the sensitivity of the host species is increased by using as vaccine strain its revertant, as a suppressor mutant still having the attenuation or/and envelope markers. 2.3 Different variants of the live vaccine as well as of a special live vaccine for chickens and chicks and of their production are provided.

LIVE IN OVO VACCINE

The present invention relates generally to modified microorganisms suitable for use as live in ovo vaccines for avian species. The live in ovo vaccines of the present invention are useful for inducing immunity before or immediately after hatching against a virulent form of the modified microorganism or a microorganism immunologically related to the modified microorganism or a virulent organism or virus carrying an antigenic determinant expressed by the modified microorganism in the live vaccine. The subject live in ovo vaccines are particularly efficacious in enhancing the survival rate of newly--hatched poultry birds.

IMMUNOGENIC HYBRID PROTEIN OPRF-OPRL DERIVED FROM PSEUDOMONAS AERUGINOSA MEMBRANE PROTEINS

The present invention relates to a hybrid protein comprising the Pseudomonas aeruginosa outer membrane protein I (OprI) which is fused with its amino terminal end to the carboxy-terminal end of a carboxy-terminal portion of the Pseudomonas aeruginosa outer membrane protein F (OprF), as well as to monoclonal or polyclonal antibodies against this hybrid protein. Both, the hybrid protein and, the antibodies directed to the hybrid protein confer protection against an infection by Pseudomonas aeruginosa to laboratory animals or man.

NON-VIRULENT MYCOPLASMA SYNOVIAE AND VACCINE THEREOF

The present invention provides NAD-independent Mycoplasma synoviae of strain MS1 . The invention also refers to microbiological cultures comprising Mycoplasma syno viae of this strain. Next to this, the invention refers to live vaccines derived from th ese strains, for the protection of poultry against Mycoplasma synoviae infection. Furthermore, th e invention provides methods for the preparation of such vaccines. Also, the use o f NAD-independent Mycoplasma synoviae strains for the preparation of live vaccines for the protection of poultry against Mycoplasma synoviae infection is disclosed.

IMMUNIZING COMPOSITIONS AND METHODS OF USE

The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccharide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods making and methods of using such compositions.

Method of vaccination of newly hatched poultry

A method of delivering a protein to domestic poultry by administering to the poultry by whole body spray an effective amount of a live avirulent derivative of an enteropathogenic bacterium that contains a recombinant gene encoding the protein.

Immunostimulation methods for providing disease protection in poultry

ALIVE FOR THE PREVENTION OF THE SALMONELLOSE OF THE WATER BIRDS AND PROCEEDED VACCINE FOR SA PREPARATION

ALIVE FOR THE PREVENTION OF THE SALMONELLOSE OF THE WATER BIRDS AND PROCEEDED VACCINE FOR SA PREPARATION

CAMPYLOBACTER VACCINE

PURPOSE: Campylobacter vaccine is provide to achieve a vaccine effective against colonization of Campylobacter and an antigenic protein effective for preparation of the vaccine. CONSTITUTION: The campylobacter vaccine including an antiserum to an amastigote Campylobacter strain is used for animals in order to prevent the colonization of Campylobacter. An antigenic protein is capable of being checked visually after the incubation of a western blotting using an antibody to a variant to amastigote Campylobacter jejuni in a western blotting of the Campylobacter jejuni protein, but the antigenic protein is unable of being checked visually after the incubation of the blotting using an antibody to a wild type Campylobacter jejuni in a western blotting of the Campylobacter jejuni protein. COPYRIGHT 2001 KIPO ...

Passive vaccine for the prevention of campylobacter colonization, and its preparation method

VACCINE AGAINST E.COLI SEPTICAEMIA IN POULTRY

METODO PARA LA PREPARACION DE UNA VACUNA PARA PROTEGER AVES DE CORRAL CONTRA SEPTICEMIA CAUSADA POR ESCHERICHIA COLI, QUE COMPRENDE LAS ETAPAS DE: (A1) CULTIVAR CELULAS DE E.COLI PRODUCTORAS NATURALMENTE DE FIMBRIAS F11, U ORGANISMOS RECOMBINANTES TRANSFORMADOS CON PARTE DE LA SECUENCIA DE ACIDO NUCLEICO QUE CODIFICA FIMBRIAS F11 OBTENIBLES DEL PLASMIDO PPIL 291- 15 CON EL CUAL LA CEPA DEE.COLI AM1727 SE TRANSFORMA Y QUE ESTA DEPOSITADO EN LA COLECCION NACIONAL DE CULTIVO DE MICROORGANISMOS DEL LNSTITUTO PASTEUR EN PARIS BAJO EL N° I-709; (A2)RECOGER MATERIAL QUE CONTIENE FIMBRIAS F11 O SECCIONES INMUNOGENAS DE LAS MISMAS; (B1) CULTIVAR ORGANISMOS RECOMBINANTES TRANSFORMADOS CON PARTE DE LA SECUENCIA DE ACIDO NUCLEICO QUE CODIFICA FIMBRIAS F11 OBTENIBLES DEL PLASMIDO PPIL 291-15 CON EL CUAL LA CEPA DE E.COLI AM1727 SE TRANSFORMA Y QUE ESTA DEPOSITADO EN LA COLECCION NACIONAL DE CULTIVO DE MICROORGANISMOS DEL INSTITUTO PASTEUR BAJO EL N° I-709; (B2) RECOGER MATERIAL QUE CONTIENE ORG ANISMOS ...

Live vaccines

The present invention discloses a novel approach to attenuating bacteria and for their use as live vaccines. The vaccines can be used in human and animal medicine. In particular, there is disclosed a method of attenuating a bacteria by mutating a gene concerned with the regulation of one or more genes concerned with expression of outer membrane proteins, particularly porin proteins.

Live vaccines

Live vaccine with enhanced stability

... 2.1 The safety of bacterial live vaccine strains is guaranteed by deletions whose stability in respect of in vivo repair is in the order of about 10-12. The stringent requirements of the World Health Organisation and the widespread opinion about the alleged lack of safety on use of live vaccines under practical conditions make it appear necessary to increase the safety margin existing now by a further increase by at least a factor of 10-7. 2.2 The stability of a live vaccine prepared from at least one metabolic drift-attenuated, immunogenic, stable, single or multiple marker live vaccine strain with or without envelope mutation and an optimal degree of attenuation adapted to the susceptibility of the host species is increased using as vaccine strain its revertant which, as suppressor mutant, also has the attenuation and/or envelope markers. 2.3 Various variants of the live vaccine and a specific live vaccine for fowls and chicks and the production thereof are indicated.

Haemophilus Paragallinarum-Impfstoffe.

A method for generating birnavirus from synthetic RNA transcripts

?-1,4-MANNOBlOSE-CONTAlNING COMPOSITION

동물체내에서의 살모넬라균의 정착을 억제하여 살모넬라균을 체외로 효율적으로 배출할 수 있는 β-1,4-만노비오스 함유 조성물 및 그 제조방법, β-1,4-만노비오스 함유 조성물을 포함하는 사료용 첨가제나, β-1,4-만노비오스 함유 조성물을 배합한 사료를 제공하는 것이다. 만난 함유 천연물에 만난 분해효소를 작용시켜, 분해전의 만난에 대해서 적어도 10중량% 이상의 β-1,4-만노비오스를 생성시키는 것을 특징으로 하는 β-1,4-만노비오스 함유 조성물의 제조방법, 만난 함유 천연물에 만난 분해효소를 작용시켜 얻어지고, 건조물 환산으로 적어도 10중량% 이상의 β-1,4-만노비오스를 포함하는 것을 특징으로 하는 β-1,4-만노비오스 함유 조성물, β-1,4-만노비오스 함유 조성물을 포함하는 사료용 첨가제, 및 β-1,4-만노비오스 함유 조성물을 배합한 사료이다.

Live vaccine

.beta.-1,4-mannobiose-containing composition

The present invention is to provide a .beta.-1,4-mannobiose-containing composition which can inhibit colonization of salmonella in animal body and effectively excrete salmonella outside the body and the method for producing thereof, a feed additive containing the .beta.-1,4-mannobiose-containing composition, and a feed blended with the .beta.-1,4-mannobiose-containing composition. The present invention is intended to provide a method for producing the .beta.-1,4-mannobiose-containing composition wherein a mannan degrading enzyme is functioned to a mannan-containing natural material for producing at least 10% by weight of .beta.-1,4-mannobiose based on the mannan before the degradation, the .beta.-1,4-mannobiose-containing composition prepared through the function of a mannan degrading enzyme to a mannan-containing natural material, which contains at least 10% by weight of .beta.-1,4-mannobiose in terms of dry matter, a feed additive containing the .beta.-1,4-mannobiose-containing composition, and a feed blended with the .beta.-1,4-mannobiose-containing composition.

Live vaccines

Attenuated microorganism for use in immunoprophylaxis in which the attenuation is brought about by the presence of a mutation in the DNA sequence of the microorganism which encodes, or which regulates the expression of DNA encoding a pro-tein that is produced in response to environmental stress, the microorganism optionally being capable of expressing DNA encod-ing a heterologous antigen.

Fowl cholera vaccine

Abstract of the Disclosure: The present invention relates to a live vaccine against Pasteurella multocida, for application of poultry by injection, per os or as aerosol, containing an attenuated non-virulent genetically stable strain of Pasteurella multocida, to a process for producing an attenuated genetically stable non-virulent strain of Pasteurella multocida, which comprises cultivating a virulent field strain, selecting after 18 hours at 37°C colonies of uniform size, of about 4 to 5 mm diameter, suspending these in a pH 5.5 buffer, subjecting same to a mutagen at a concentration causing a mortality of 90-99 % after 30 minutes at 37°C, centrifuging the microorganisms, washing sane, plating same and selecting colonies of not more than 2.5 to 3 mm diameter after 18 hours at 37°C, purifying by reisolation of single colonies, testing for antigenic specificity and virulence, and selecting avirulent genetically stable immunologically effective mutants fur use in vaccines, and to a process for the vaccination of poultry which comprises applying such a vaccine by injection, per os or as aerosol.

MUNICIPAL COMPOSITIONS AND METHODS OF USE

VACCINE WITH E.COLI SEPTICAEMIA OF SPRING CRAFTS

Cpg dna adjuvant in avian vaccines

Methods for treating mastitis in a milk producing animal

The present invention provides methods for treating mastitis in a milk producing animal. The methods include administering compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter.

Immunizing compositions and methods of use

The present invention provides compositions including antibodies that specifically bind at least one siderophore receptor polypeptide from a gram positive microbe. The present invention also provides methods of making and methods of using such compositions.

Vaccine against e.coli septicaemia in poultry

Method for preventing and treating coccidiosis

A method for preventing and treating parasitic infections in animals by administering a lysine analog, such as EACA, to the animals on a continuous basis. In the preferred embodiment, the method of the present invention is directed to preventing and treating coccidial infections in poultry by adding EACA to the daily diet of a poultry flock. EACA may also be administered in ovo before hatching. The administration of EACA enhances the natural immune response of the poultry to the invading coccidial organisms and enables the poultry to combat the parasites without the need for antibiotics. Another aspect of the present invention involves preventing parasitic diseases in humans and animals by prophylactically administering a serine protease inhibitor, such as EACA, as an adjuvant in conjunction with a conventional vaccine effective against the target parasite.

Flagellin gene, flac of campylobacter

Purified and isolated nucleic acid molecules are provided which encode a FlaC flagellin protein of a strain of Campylobacter, particularly C. jejuni, or a fragment or an analog of the FlaC flagellin protein. The nucleic acid molecules may be used to produce proteins free of contaminants derived from bacteria normally containing the FlaA or FlaB proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecules, proteins encoded thereby and antibodies raised against the proteins, may be used in the diagnosis of infection.

Immunization preparations and their use

Immunogenic Hybrid Protein OprF-Oprl Derived from Pseudomonas aeruginosa Membrane Protein

본 발명은 슈도모나스 에루지노사 외막 단백질 F(OprF)의 카복시-말단 부분의 카복시 말단 끝에 그의 아미노 말단이 융합된 슈도모나스 에루지노사 외막 단백질 I(OprI)를 포함하는 하이브리드 단백질 및 상기 하이브리드 단백질에 대한 모노클로날 또는 폴리클로날 항체에 관한 것이다. 단백질 및 하이브리드 단백질 및 하이브리드 단백질에 대한 항체 모두는 실험 동물 또는 사람을 슈도모나스 에루지노사 감염으로부터 보호한다.

Compositions including gram negative siderophore receptor proteins and methods of use

The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.

ANOMIZING OR SPRAYING DEVICE FILLED WITH A KILLED VACCINE.

Methods for detecting antibody that specifically bind a siderophore receptor polypeptide

The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccharide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.

Turkey rhinotracheitis vaccine

A live vaccine against Alcaligenes faecalis, for application to turkeys, containing a temperature-sensitive non-virulent genetically stable strain of Alcaligenes faecalis having good immunizing capabilities and the absence of adverse side-effects.

Live salmonella typhi-murium vaccine

β-1,4-mannobiose-containing composition

動物体内でのサルモネラ菌の定着を抑制してサルモネラ菌を体外へ効率的に排出することができるβ−１，４−マンノビオース含有組成物及びその製造方法、β−１，４−マンノビオース含有組成物を含む飼料用添加剤や、β−１，４−マンノビオース含有組成物を配合した飼料を提供するものである。マンナン含有天然物にマンナン分解酵素を作用させ、分解前のマンナンに対して少なくとも１０重量％以上のβ−１，４−マンノビオースを生成させることを特徴とするβ−１，４−マンノビオース含有組成物の製造方法、マンナン含有天然物にマンナン分解酵素を作用させて得られ、乾物換算で少なくとも１０重量％以上のβ−１，４−マンノビオースを含むことを特徴とするβ−１，４−マンノビオース含有組成物、β−１，４−マンノビオース含有組成物を含む飼料用添加剤、及びβ−１，４−マンノビオース含有組成物を配合した飼料である。 Including a β-1,4-mannobiose-containing composition that can suppress colonization of Salmonella in an animal body and efficiently discharge Salmonella to the outside of the body, a method for producing the same, and a β-1,4-mannobiose-containing composition The present invention provides a feed containing a feed additive or a β-1,4-mannobiose-containing composition. A β-1,4-mannobiose-containing composition characterized in that a mannan-degrading enzyme is allowed to act on a mannan-containing natural product to produce at least 10% by weight of β-1,4-mannobiose with respect to mannan before decomposition. Β-1,4-mannobiose-containing, characterized in that it is obtained by allowing a mannan-degrading enzyme to act on a mannan-containing natural product and contains at least 10% by weight of β-1,4-mannobiose in terms of dry matter It is the feed which mix | blended the additive for feed containing a composition, (beta) -1, 4- mannobiose containing composition, and (beta) -1,4-mannobiose containing composition.

Immunogenic hybrid protein OprF-Oprl available from membrane proteins from Pseudomonas aeruginosa

Immunogenic hybrid protein OprF-Oprl derived from Pseudomonas aeruginosa membrane proteins

The present invention relates to a hybrid protein comprising the Pseudomonas aeruginosa outer membrane protein I (OprI) which is fused with its amino terminal end to the carboxy-terminal end of a carboxy-terminal portion of the Pseudomonas aeruginosa outer membrane protein F (OprF), as well as to monoclonal or polyclonal antibodies against this hybrid protein. Both, the hybrid protein and the antibodies directed to the hybrid protein confer protection against an infection by Pseudomonas aeruginosa to laboratory animals or man.

Mycoplasma vaccine

β-1,4-mannobiose-containing composition

Use of opri lipoprotein from pseudomonas as a th1 inducing natural adjuvant for heterologous antigens

The present invention relates to the use of the major OprI lipoprotein of Pseudomonas aeruginosa to elicit a Type-1 immune response towards a heterologous antigen. The invention relates specifically to the use of Oprl - antigen fusion proteins to elicit said Typ-1 response. More particurarly, the present invention is directed to pharmaceutical formulations comprising Oprl and/or Oprl fusion proteins, optionnaly together with a suitable excipient, to stimulate the Th1 dependent, cellular immune response.

Immunizing compositions and methods of use

The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.

Vaccine for domestic fowl colibacillosis

(57)【要約】本公報は電子出願前の出願データであるた め要約のデータは記録されません。

POULTRY COLIBACILLOSIS VACCINE.

A vaccine useful for the protection of poultry from colibacillosis infections comprises as an active ingredient pre-inactivated and ultrasonicated E. coli cells. Poultry may be protected from colibacillosis infections by inoculating said vaccine into poultry through the cloaca.

Live vaccines

Attenuated microorganism for use in immunoprophylaxis in which the attenuation is brought about by the presence of a mutation in the DNA sequence of the microorganism which encodes, or which regulates the expression of DNA encoding a pro-tein that is produced in response to environmental stress, the microorganism optionally being capable of expressing DNA encod-ing a heterologous antigen.

Composition and method for inhibiting salmonella and campylobacter colonization in poultry

One embodiment of the present invention is directed to the use of a novel competitive exclusion bacterial composition to prevent or reduce Salmonella or Campylobacter colonization in poultry.

Vaccines comprising attenuated salmonella having mutations in the ompr genes

The present invention discloses a novel approach to attenuating bacteria and for their use as live vaccines. The vaccines can be used in human and animal medicine. In particular, there is disclosed a method of attenuating a bacteria by mutating a gene concerned with the regulation of one or more genes concerned with expression of outer membrane proteins, particularly porin proteins.

LIVING VACCIN AGAINST PASTEURELLA MULTOCIDA

Fowl cholera vaccine and process for producing an attenuated non-virulent strain of pasteurella multocida

Active immunization using a siderophore receptor protein

Live bacterial vaccine

Mycoplasma vaccine

Immunogenic hybrid protein OprF-Oprl derived from Pseudomonas aeruginosa membrane proteins

The present invention relates to a hybrid protein comprising the Pseudomonas aeruginosa outer membrane protein I (OprI) which is fused with its amino terminal end to the carboxy-terminal end of a carboxy-terminal portion of the Pseudomonas aeruginosa outer membrane protein F (OprF), as well as to monoclonal or polyclonal antibodies against this hybrid protein. Both, the hybrid protein and the antibodies directed to the hybrid protein confer protection against an infection by Pseudomonas aeruginosa to laboratory animals or man.

Process for producing micoplasma vaccine

Patent DE2836507C2

New bacterium causing poultry disease and vaccine derived thereof

PCT No. PCT/EP93/02873 Sec. 371 Date Jun. 9, 1994 Sec. 102(e) Date Jun. 9, 1994 PCT Filed Oct. 14, 1993 PCT Pub. No. WO94/09114 PCT Pub. Date Apr. 28, 1994The present invention relates to a novel bacterial respiratory poultry disease and the identification of the causative agent Ornithobacterium rhinotracheale. A vaccine derived from this agent was effective in preventing the disease in chickens challenged with the virulent field strains.

Vaccines for fowl colibacillosis

Abstract: The present invention is directed to a vaccine useful for the protection of poultry from colibacillosis infections which comprises as an active ingredient pre-inactivated and ultrasonicated E. coli cells. The invention is further directed to a method for protecting poultry from colibacillosis infections which comprises inoculating poultry through the cloaca with said vaccine.

New bacterium causing poultry disease and vaccine derived thereof

CpG DNA Adjuvant in Avian Vaccines

A CpG DNA adjuvant in avian vaccines is disclosed, which includes an immunostimulatory oligodeoxynucleotide (ODN) having a plurality of TCG tandem repeats at a 5′end, a poly-G structure at a 3′ end, and at least one unmethylated CpG motif with avian specific flanking sequences at two ends thereof between the 5′ end and the 3′ end. The CpG DNA adjuvant in avian vaccines is advantageous to carry out large-scale production, specifically enhance avian innate and adaptive immune responses, and the CpG DNA adjuvant is hardly to be digested by DNase due to its particular structures.

Mixed vaccine for animal Salmonella infection

본 발명은 국내 유행 살모넬라균 혈청그룹인 그룹 B, C 및 D에 속하는 각각의 살모넬라균주의 세포외막단백질(OMP)을 면역항원으로 함유하는 동물 살모넬라 감염 예방용 혼합백신을 제공한다. 본 발명은 바람직하게는 상기 그룹 B에 속하는 살모넬라균으로는 살모넬라 티피뮤리움을, 그룹 C에 속하는 살모넬라균으로는 살모넬라 브렌더럽을, 및 그룹 D에 속하는 살모넬라균으로는 살모넬라 엔테라이티디스 균주가 선택되어지는 혼합백신을 제공한다. The present invention provides a mixed vaccine for preventing the Salmonella infection of animals containing the extracellular membrane protein (OMP) of each Salmonella strain belonging to the domestic epidemic Salmonella serogroups B, C and D as an immunogen. According to the present invention, Salmonella typhimurium is preferably selected from Salmonella belonging to Group B, Salmonella blender is selected from Salmonella belonging to group C, and Salmonella enteritidis strain is selected from Salmonella belonging to group D. Provide a combined vaccine.

Immunizing compositions and methods of use

The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.

Vaccine against e.coli septicamea in poultry

내용 없음. No content.

Συνθεσεις ανοσοποιησης και μεθοδοι χρησης

Η παρούσα εφεύρεση παρέχει συνθέσεις που περιλαμβάνουν πολυπεπτιδικούς υποδοχείς σιδηροφόρων και πορίνες από gram αρνητικά μικρόβια, και κατά προτίμηση, λιποπολυσακχαρίτη σε συγκέντρωση όχι μεγαλύτερη από αυτή περίπου των 10,0 μονάδων ενδοτοξίνης ανά χιλιοστό του λίτρου. Η παρούσα εφεύρεση επίσης παρέχει μεθόδους κατασκευής και μεθόδους χρήσης τέτοιων συνθέσεων.

Gebrauch von opri lipoprotein aus pseudomonas als th1 induzierendes natürliches adjuvans für heterologe antigene

Aktive immunisierung gegen ein siderophores rezeptorprotein

High energy electron beam irradiation for the production of immunomodulators in poultry

Populations of Salmonella in animals may be substantially reduced by treatment with a vaccine composition which has been produced by exposing whole, intact cells of a Salmonella species to irradiation with an electron beam under conditions effective to kill the cells. The electron beam irradiated cells of Salmonella are effective for stimulating protective immune responses in the animals against the Salmonella . Induction of these immune responses significantly reduces or eliminates the colonization of the animal by the Salmonella , and consequently reduces or eliminates the shedding of Salmonella in the feces of the animals.

Imunização activa da utilização de uma proteina receptora de sideroforos

Zusammensetzungen zur immunisierung sowie deren verwendung

Lebende vakzine

Vaccine for poultry

A method of delivering a protein to domestic poultry by administering to the poultry by whole body spray an effective amount of a live avirulent derivative of an enteropathogenic bacterium that contains a recombinant gene encoding the protein.

Nicht-virulentes mycoplasma synoviae und impfstoffe desselben

Eljárás Birnavírus előállítására szintetikus RNS-átiratokból

A találmány élő Birnavírűs - ilyen a brűsitis infectiősa betegségvírűsa (IBDV = Infectiőűs Bűrsal Disease Virűs), amely egyBirnaviridae családhőz tartőzó szegmentált kétszálú (ds)RNS vírűs -előállítására kifejlesztett rendszerre vőnatkőzik, amelyben klónőzőttDNS-ről származó szintetikűs átiratőkat szerkesztettek, amelyek azIBDV A. és B. szegmentűmainak teljes kódőló, illetve nemkódőló régióittartalmazza. A két szegmentűm szintetikűs RNS-eit linearizáltplazmidők T7 RNS pőlimerázzal végzett in vitrő transzkripciójávalállítőtták elő. Verő sejtek trasnzfekciója a két szegmentűm kőmbináltplűsz-szensz átirataival, a transzfekciót követően már 36 óra múlvafertőző vírűst hőz létre. ŕ

A method for generating birnavirus from synthetic rna transcripts

Verfahren zur erzeugung des virus der infektiösen bursitis aus synthetischen rns-transkripten

Micoplasma synoviae no virulento y vacuna del mismo.

La presente invencion provee Mycoplasma synoviae independiente de NAD de la cepa MS1. La invencion también se refiere a cultivos microbiologicos que comprenden Mycoplasma synoviae de esta cepa. Después de esto, la invencion se refiere a vacunas vivas derivadas de estas cepas, para la proteccion de aves contra infeccion de Mycoplasma synoviae. Además, la invencion provee métodos para la preparacion de dichas vacunas. También, se describe el uso de cepas de Mycoplasma synoviae independientes de NAD para la preparacion de vacunas vivas para la proteccion de aves contra infeccion de Mycoplasma synoviae.

Mycoplasma synoviae and its use

Impfstoff für geflügel

Method of vaccination of newly hatched poultry

A method of delivering a protein to domestic poultry by administering to the poultry by whole body spray an effective amount of a live avirulent derivative of an enteropathogenic bacterium that contains a recombinant gene encoding the protein.

조류 대장균증 백신 조성물 및 이의 제조방법

본 발명은 조류 병원성 대장균 분류방법, 병원성 대장균증 백신 조성물, 이의 제조방법 및 상기 백신 조성물을 투여하여 가금류에서 대장균증을 예방하거나 경감시키는 방법에 관한 것이다.

Non-virulent mycoplasma synoviae and vaccine thereof

Nicht-virulentes Mycoplasma synoviae und Impfstoffe desselben

Non-virulent mycoplasma synoviae and vaccine thereof

Mycoplasma synoviae nao virulento e sua vacina

Mycoplasma synoviae no virulento y vacuna de este.

LA PRESENTE INVENCION PROPORCIONA MYCOPLASMA SYNOVIAE DE LA CEPA MS1 INDEPENDIENTE DE NAD. LA INVENCION SE REFIERE ASIMISMO A CULTIVOS MICROBIOLOGICOS QUE COMPRENDEN MYCOPLASMA SYNOVIAE DE ESTA CEPA. ADICIONALMENTE, LA INVENCION SE REFIERE A VACUNAS VIVAS DERIVADAS DE ESTAS CEPAS, PARA LA PROTECCION DE AVES DE CORRAL CONTRA LA INFECCION POR MYCOPLASMA SYNOVIAE. ADICIONALMENTE, LA INVENCION PROPORCIONA METODOS PARA LA PREPARACION DE DICHAS VACUNAS. ASIMISMO, SE DESCUBRE EL USO DE CEPAS DE MYCOPLASMA SYNOVIAE INDEPENDIENTE DE NAD PARA LA PREPARACION DE VACUNAS VIVAS PARA LA PROTECCION DE AVES DE CORRAL CONTRA LA INFECCION POR MYCOPLASMA SYNOVIAE.

vacina viva para a proteÇço de aves domÉsticas, processo para sua preparaÇço, e, uso de mycoplasma synoviae.

Non-virulent mycoplasma synoviae and vaccine thereof

Attenuiertes Lebendvakzin zur Verwendung in Eiern

Non-virulent mycoplasma synoviae and vaccine thereof

Live in ovo vaccine

Attenuiertes lebendvakzin zur verwendung in eiern

Attenuiertes Lebendvakzin zur Verwendung in Eiern

Avirulens Mycoplasma synoviae, és az ezt tartalmazó vakcina

A találmány NAD-independens Mycőplasma synőviae MS1 törzsre, a fentitörzs mikrőbiőlógiai tenyészeteire, és a fenti törzsből származó élővakcinákra vőnatkőzik, amelyek barőmfiak Mycőplasma synőviae fertőzéseellen szőlgáltatnak védelmet. A találmány tárgya tővábbá eljárás afenti vakcinák előállítására, és a NAD-independens Mycőplasma synőviaetörzs alkalmazása barőmfiak Mycőplasma synőviae fertőzés ellenivédelmére szőlgáló élő vakcinák előállítására. ŕ

A method for generating birnavirus from synthetic rna transcripts

A system for the generation of live Birnavirus such as infectious bursal disease virus (IBDV), a segmented double-stranded (ds)RNA virus of the Birnavirdae family, using synthetic transcripts derived from cloned DNA has been developed. Independent full-length cDMA clones were constructed which contained the entire coding and noncoding regions of RNA segments A and B of IBDV, respectively. Synthetic RNAs of both segments were produced by in viro transcription of linearized plasmids with T7 RNA polymerase. Transfection of Vero cells with combined plus-sense transcripts of both segments generated infectious virus as early as 36 hours post-transfection. The development of a reverse genetics system for dsRNA viruses will greatly facilitate studies of the regulation of viral gene expression pathogenesis, and design of a new generation of live and inactivated vaccines.

Method of obtaining birnavirus from synthesis rna transcriptions

En metode for Õ fremstille birnavirus fra syntetiske RNA-transkripter

从合成的rna转录物制备双rna病毒的方法

利用起源于克隆的DNA的合成转录物已经开发了制备活的双RNA病毒如感染性的囊病病毒(IBDV),一种双RNA病毒家族的形成区段的双链(ds)RNA病毒的系统。构建了独立的全长cDNA克隆,它们分别含有IBDV的RNAA和B区段的整个编码和非编码区。利用T7RNA聚合酶对线性化质粒体外转录产生两个区段的合成RNA。利用合并的两区段的正意义转录物转染非洲绿猴肾细胞,在早至转染后36小时产生感染性病毒。dsRNA病毒的反遗传系统的开发将大大简化病毒基因表达的调节和病理的研究和产生新的活和失活疫苗的设计。

Método para gerar birnavìrus a partir de trancritos de rna sintético.

<B>"MéTODO PARA GERAR BIRNAVìRUS A PARTIR DE TRANSCRITOS DE RNA SINTéTICO"<D>. A presente invenção trata de um sistema que foi desenvolvido para a geração de Birnavírus ativo, tal como o vírus da doença bursal infecciosa (IBDV), um vírus segmentado de RNA duplamente espiralado (ds) da família dos Birnaviridae, usando transcritos sintéticos derivados de DNA clonado. Os clones de cDNA independentes de inteira extensão, foram construídos contendo regiões de inteira codificação e descodificação dos segmentos A e B do RNA, do IBDV, respectivamente. Os RNAs sintéticos de ambos os segmentos foram produzidos por meio de transcrição in vitro de plasmídios linearizados com polimerase de RNA T7. A transfecção das células de Vero combinado com os transcritos mais sensíveis de ambos os segmentos gerou o vírus infeccioso logo nas 36 horas após a transfecção. O desenvolvimento de um sistema genético inverso para vírus de RNA duplamente espiralados, irá facilitar acentuadamente as pesquisas de regulação da expressão do gene viral, da patogênese e o projeto de uma nova geração de vacinas ativas e inativadas.

Způsob přípravy Birnavirusu, živý virus, syntetická RNA, transfekce, cDNA, rekombinantní vektor, buňka, vakcína

Sposób otrzymywania żywego Birnawirusa, wirus wytworzony tym sposobem oraz szczepionka zawierająca wymieniony wirus

1 Sposób otrzymywania zywego Birnawirusa, w którym Birnawirusem jest wirus zakaznej choroby kalet- kowej (IBDV), znamienny tym, ze obejmuje nastepujace etapy. - otrzymanie cD N A segmentu A i segmentu B genomu Birnawirusa, - przetworzenie wym ienionego cDNA w celu wyprodukowania syntetycznych transkryptów RNA, gdzie wspomniane transkrypty RNA sa dodatnio polarnymi transkryptami RNA wspomnianych segmentów A i B, - dokonanie transfekcji komórek zywicielskich wspomnianymi syntetycznymi transkryptami RNA, - inkubacje wspomnianych komórek zywicielskich w pozywce kulturowej oraz - wyizolowanie zyw ego, zakaznego Birnawirusa ze wspomnianej pozywki kulturowej 7 Zywy, chimeryczny wirus zakaznej choroby kaletkowej (IBDV), gdzie wymieniony wirus jest wytwo- rzony sposobem, obejmujacym etapy - otrzymywania cD N A wirus zakaznej choroby kaletkowej (IBDV) segmentów A i B, - kopiowania wym ienionego cDNA w celu wytworzenia syntetycznych transkryptów RNA wymienionych segmentów A i B, - transfekcje komórki zywiciela wymienionymi transkryptami syntetycznego RNA, - inkubacji wymienionych komórek zywiciela w pozywce, oraz - wyizolowania zywego, chimerycznego wirus zakaznej choroby kaletkowej (IBDV) z wymienionej pozywki 9 Szczepionka, zawierajaca zywy, chimeryczny wirus zakaznej choroby kaletkowej (IBDV), znamienna tym, ze wspomniany wirus wytworzony jest sposobem, obejmujacym etapy - otrzymywania cD N A wirus zakaznej choroby kaletkowej (IBDV) segmentów A i B, - kopiowania wym ienionego cDNA w celu wytworzenia syntetycznych transkryptów RNA wymienionych segmentów A i B, - transfekcje komórki zywiciela wymienionymi transkryptami syntetycznego RNA, - inkubacji wymienionych komórek zywiciela w pozywce, oraz - wyizolowania zyw ego, chimerycznego wirus zakaznej choroby kaletkowej (IBDV) z wymienionej pozywki, w której wymieniony zywy chimeryczny Birnawirus jest przed podaniem pozbawiany aktywnosci lub oslabiany PL 190220 B 1 PL PL PL PL PL

A reverse genetics system for dsRNA viruses that generates birnavirus, such as infectious bursal disease virus, from synthetic RNA transcripts

En metode for a fremstille birnavirus fra syntetiske RNA-transkripter

A method for generating birnavirus from synthetic rna transcripts